WOBURN, Mass., June 13, 2017 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced today that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it has regained compliance with the NASDAQ Capital Market’s minimum bid price continued listing requirement. The letter noted that as of June 12, 2017, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with NASDAQ Marketplace Rule 5550(a)(2) and NASDAQ considers the matter closed.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. Yield10 is leveraging its technology platforms and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and corn. Yield10 is headquartered in Woburn, MA and has an Oilseeds center of excellence in Saskatoon, Canada.
For more information about the company, please visit www.yield10bio.com. (YTEN-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, Yield10’s ability to continue to maintain compliance with NASDAQ listing rules, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.
Contacts: Yield10 Bioscience: Lynne H. Brum, (617) 682-4693, [email protected] Investor Relations Contact: Amato and Partners, LLC 90 Park Avenue, 17th Floor New York, NY 10016 [email protected]


FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 



